Latest news

Thumbnail image for Final NICE nod for Sanofi’s Kevzara

Final NICE nod for Sanofi’s Kevzara

The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis (RA).

2nd November 2017

Thumbnail image for EU OKs low-dose Xarelto to prevent recurrent VTE

EU OKs low-dose Xarelto to prevent recurrent VTE

A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.

2nd November 2017

Thumbnail image for NICE back Roche’s Tecentriq for CDF

NICE back Roche’s Tecentriq for CDF

The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.

1st November 2017

Thumbnail image for AZ, Incyte to test lung cancer combo in PhIII

AZ, Incyte to test lung cancer combo in PhIII

AstraZeneca and MedImmune have expanded their clinical collaboration with Incyte to carry out a late-stage trial assessing an experimental combination therapy for lung cancer.

1st November 2017

Thumbnail image for GW completes Epidiolex submission

GW completes Epidiolex submission

GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy.

31st October 2017

Thumbnail image for AZ farms out rare disease therapy to Mereo

AZ farms out rare disease therapy to Mereo

AstraZeneca has licensed an experimental rare disease therapy to UK-based Mereo BioPharma, as it continues to shed products outside of its area of strategic focus.

31st October 2017

Thumbnail image for Concept buys Scottish CRO Aquila

Concept buys Scottish CRO Aquila

Manchester, UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organisation Aquila BioMedical.

31st October 2017

Thumbnail image for MSD pulls EU filing for Keytruda combo

MSD pulls EU filing for Keytruda combo

MSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).

30th October 2017

Previous  --   13 14 15 16 17 18 19 20 21 22   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download